GKB Ophthalmics Ltd Stock Price Today (NSE: GKB)

GKB Ophthalmics Ltd

60.701.37 (2.21%)
Market Closed

Fundamental Score

...

GKB Ophthalmics Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

GKB Ophthalmics Ltd share price today is 60.70, down 2.21% on NSE/BSE as of 18 June 2026. GKB Ophthalmics Ltd (GKB) is a Small-cap company in the Medical Equipment & Supplies sector with a market capitalisation of 29.99 (Cr). The 52-week high for GKB share price is 91.70 and the 52-week low is 45.25. The company has a Return on Equity (ROE) of -12.66% and a debt-to-equity ratio of 0.28.

GKB Ophthalmics Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
70.74
Low
60.61
Volume
1.4K
Change
-3.70%

GKB Ophthalmics Ltd share price chart: -3.70% return over the past month. 52-week high ₹91.70, 52-week low ₹45.25.

GKB Ophthalmics Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
63.1563.1560.6060.70913.00 (Cr)
63.7363.7362.0762.0756.00 (Cr)
62.0064.5062.0063.731.25K (Cr)
67.8570.3564.5065.007.33K (Cr)
67.2069.5066.9267.857.05K (Cr)
68.0070.7468.0070.443.38K (Cr)
69.9969.9966.3067.38447.00 (Cr)
67.8069.0067.4968.801.57K (Cr)
66.6466.6466.5466.55366.00 (Cr)
63.5565.9863.5565.02410.00 (Cr)

GKB Ophthalmics Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
63.7363.7360.6060.70-4.75%
69.0070.7460.6163.73-7.64%
51.5176.9051.5168.49+32.96%
55.5064.9951.0552.50-5.41%
58.0074.5051.4558.86+1.48%
50.9960.0048.1557.11+12.00%
59.8061.3545.2551.24-14.31%
69.3669.3654.3559.62-14.04%
67.3073.6062.3567.67+0.55%
79.8083.9065.0067.27-15.70%
77.0091.7074.0077.42+0.55%
75.9980.0070.0073.10-3.80%

AI Research Briefing

Powered by Gemini · 2026-04-10

Micro-cap turnaround story built on fumes; avoid until real cash flow emerges.

Research Confidence
4.0/10Low
MICRO-CAP DARK HORSEBreakdown: 1M: -12.06% | 3M: -22.04% | 6M: -20.63% [cite: brief]Nonex P/E vs Industry P/E of 47.87x. Impossible to value; speculative.

WHAT'S HAPPENING NOW (last 2-4 weeks)

GKB Ophthalmics has been primarily focused on regulatory compliance and corporate governance. Key activities include:

* Confirmation of non-applicability of SEBI circular for large corporates.

* Submission of compliance certificates under SEBI regulations.

* An independent directors meeting was held on March 18, 2026, covering board effectiveness, chairperson evaluation, and information flow.

CORE STORY (THE REAL GAME)

Why Now
  • Recent positive quarterly results (revenue and profit growth)
  • Independent directors meeting suggests focus on corporate governance
  • Overall positive sentiment in the medical equipment sector
Potential Catalysts
  • Sustained profitability in upcoming quarters
  • Significant order wins or contract announcements
  • Successful expansion into new markets
Key Risks
  • Micro-cap: Illiquidity risk is very high.
  • Negative ROE, ROCE, and Free Cash Flow.
  • High debt/equity ratio and negative interest coverage.
Institutional Activity

Promoter holding steady at 51.06%. No significant FII/DII activity [cite: brief].

Macro Context

Indian medical devices sector has strong momentum, but GKB needs to prove it can capture this growth.

Order Book / Expansion

No major news found after live search.

Cash Flow Quality

No: Free Cash Flow 5Y: ₹-3.82 Cr [cite: brief]

3–6 Month Outlook

Needs to demonstrate consistent profitability and cash flow generation over the next 3-6 months. Monitor closely for signs of financial distress or governance issues.

Primary Thesis Risk

Inability to sustain profitability will lead to a collapse in the stock price.

For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.

Returns & Performance

Poor

Return on Equity (ROE)

-12.66%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

-6.00%

Returns generated on total capital deployed

Poor

Oper. Profit Margin (5Y Avg)

2.15%

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

GKB Ophthalmics Ltd Valuation Check

Price to Earnings (P/E)

N/A

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

47.87x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

51.06%

% shares held by company founders/management

Poor

FII Holding

1.79%

% shares held by foreign institutional investors

Poor

DII Holding

0.00%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Excellent

Profit Growth (Quarterly YoY)

231.15%

Net profit growth vs same quarter last year

Average

Revenue Growth (Quarterly YoY)

15.42%

Revenue growth vs same quarter last year

Excellent

Revenue Growth (5-Year CAGR)

13.24%

Compounded annual revenue growth over 5 years

EPS Growth (5-Year CAGR)

N/A

Earnings per share growth over 5 years

Net Profit Growth (5-Year CAGR)

N/A

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.28x

Total debt ÷ equity. Below 0.5 = financially healthy

Poor

Interest Coverage Ratio

-0.65x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

-3.82 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

GKB Ophthalmics Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of GKB across key market metrics for learning purposes.

Positive Indicators

6 factors identified

Robust Profit Growth (231.15%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture.

Strong Revenue Growth (15.42%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Consistent Growth Track Record (13.24% CAGR)

Observation: Strong 5-year sales compound annual growth rate.

Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.

Conservative Debt Levels (D/E: 0.28)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Balanced Promoter Holding (51.06%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

7 factors identified

Below-Average Return on Equity (-12.66%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Suboptimal ROCE (-6.00%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.

Margin Pressure Concerns (2.15%)

Observation: Operating margins are below industry standards.

Analysis: OPM <5% may indicate pricing pressures or cost management challenges.

Weak Interest Coverage (-0.65x)

Observation: Limited ability to service debt obligations from earnings.

Analysis: Low interest coverage raises concerns about financial stability.

Negative Free Cash Flow (₹-3.82 Cr over 5Y)

Observation: Cash outflows exceed inflows.

Analysis: Negative FCF requires analysis of capital expenditure cycle.

Limited Institutional Interest (FII+DII: 1.79%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

GKB Ophthalmics Ltd vs Medical Equipment & Supplies Peers

Peer Comparison - Medical Equipment & Supplies

Compare GKB Ophthalmics Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
29.9/100
61
₹29.99
-12.66%
Poor
-6.00%
Poor
0.3
Excellent
13.24%
Good
0.00%
60.7/100
1330
₹19506.20
53.9
Average
15.77%
Good
20.08%
Excellent
0.1
Excellent
28.38%
Excellent
19.44%
Excellent
0.18%
31.7/100
37
₹3162.93
157.5
Average
0.70%
Poor
1.08%
Poor
0.1
Excellent
0.01%
68.7/100
243
₹1488.44
57.8
Average
21.88%
Excellent
19.20%
Good
0.0
Excellent
57.51%
Excellent
9.81%
Good
0.00%
42.1/100
497
₹1363.11
50.1
Average
30.08%
Excellent
31.14%
Excellent
0.6
Good
0.00%
13.8/100
215
₹1224.98
59.6
Average
4.75%
Poor
6.91%
Poor
0.6
Good
0.00%
60.3/100
173
₹633.93
25.8
Average
36.78%
Excellent
31.12%
Excellent
0.5
Good
90.06%
Excellent
61.82%
Excellent
0.00%
68.5/100
408
₹521.17
26.2
Average
18.74%
Good
25.25%
Excellent
0.0
Excellent
29.49%
Excellent
22.80%
Excellent
0.23%
61.2/100
413
₹354.57
34.2
Average
13.58%
Average
16.35%
Good
0.4
Excellent
74.11%
Excellent
13.69%
Good
0.00%
47.7/100
187
₹294.37
32.7
Average
13.56%
Average
18.45%
Good
0.0
Excellent
0.00%
Nureca Ltd...
NURECA543264
36/100
272
₹292.61
71.2
Average
-1.12%
Poor
-0.90%
Poor
0.0
Excellent
1.98%
Average
0.00%

GKB Ophthalmics Ltd Dividend History

Annual cash dividends paid by GKB — dividend yield N/A

Financial YearDividends Paid (₹ Cr)
FY 20230.00 Cr

Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.

GKB Ophthalmics Ltd Quarterly Performance

Latest quarterly metrics for GKB — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

15.42%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

231.15%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

13.24%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

N/A

Compounded annual net profit growth over 5 years

GKB Ophthalmics Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for GKB — calculated from daily price history

51RSI 14
Neutral — RSI 51

Momentum is balanced — neither overbought nor oversold.

SMA 50
64
▼ Price below SMA 50 — Short-term bearish
SMA 200
63
▼ Price below SMA 200 — Long-term downtrend
30-Day Avg Volume
2K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

GKB Ophthalmics Ltd Financial Statements

Annual income statement, balance sheet and cash flow for GKB Ophthalmics Ltd (GKB) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for GKB Ophthalmics Ltd

About GKB (GKB Ophthalmics Ltd)

GKB Ophthalmics Ltd is a pioneering force in the global landscape of ophthalmic lens manufacturing, dedicated to enhancing vision and transforming lives through precision optics. W...ith a legacy spanning decades, GKB has established itself as a trusted provider of high-quality lens solutions, catering to the diverse needs of eye care professionals and patients worldwide. At the heart of GKB's success lies an unwavering commitment to innovation, leveraging cutting-edge technology and advanced materials to develop lenses that deliver superior clarity, comfort, and visual performance. From meticulously crafted single vision lenses to sophisticated progressive designs, GKB's comprehensive portfolio embodies excellence in optical engineering. Driven by a passion for precision and patient satisfaction, GKB Ophthalmics Ltd adheres to rigorous quality control standards throughout its manufacturing processes. Every lens undergoes meticulous inspection and testing to ensure optimal performance and compliance with international regulatory requirements. GKB understands that vision is precious and they strive to deliver products that meet the highest standards of quality and accuracy. The company's state-of-the-art facilities are equipped with advanced machinery and staffed by a team of highly skilled technicians and engineers, ensuring seamless production and consistent product quality. GKB is also committed to sustainable practices, minimizing environmental impact and promoting responsible manufacturing. Beyond manufacturing, GKB Ophthalmics Ltd fosters strong partnerships with eye care professionals, providing comprehensive support and educational resources to empower them in delivering exceptional patient care. The company believes in building lasting relationships based on trust, collaboration, and mutual success. GKB's global presence extends to numerous countries, enabling it to serve a diverse customer base and contribute to the advancement of eye care globally. With a vision to shape the future of optics, GKB Ophthalmics Ltd remains dedicated to innovation, quality, and customer satisfaction, continually striving to enhance vision and improve the lives of people around the world.

Company Details

Symbol:GKB
Industry:Medical Equipment & Supplies
Sector:Medical Equipment & Supplies

Key Leadership

Mr. Krishna Gopal Gupta
Chairman & MD
Mr. Gurudas Sawant
Chief Financial Officer
Ms. Pooja Bicholkar
Company Secretary & Compliance Officer

GKB Share Price: Frequently Asked Questions

What is the current share price of GKB Ophthalmics Ltd?

GKB Ophthalmics Ltd (GKB) trades at ₹60.70 on NSE and BSE. Market cap ₹29.99 (Cr). Educational data only.

What is the P/E ratio of GKB Ophthalmics Ltd?

GKB Ophthalmics Ltd has a P/E of N/Ax vs industry average 47.87x.

What is the Bull Run score for GKB Ophthalmics Ltd?

GKB Ophthalmics Ltd has a Bull Run score of 29.9/100 based on 25+ financial parameters.

Does GKB Ophthalmics Ltd pay dividends?

GKB Ophthalmics Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of GKB Ophthalmics Ltd?

GKB Ophthalmics Ltd has ROE of -12.66%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of GKB Ophthalmics Ltd?

GKB Ophthalmics Ltd has debt-to-equity of 0.28.

Is GKB Ophthalmics Ltd a good investment?

Bull Run gives GKB Ophthalmics Ltd a score of 29.9/100. This is not investment advice — consult a SEBI-registered advisor.